Submit Manuscript Now
Current issue Archive Authors Profile
Research Articles Issue 1 · 2021 · pp. 39–52 · Issue page

CLINICOPATHOLOGICAL ANALYSIS OF GASTRIC CANCER

AN
Antoanela Valentina CRAFCIUC1
AD
Adriana-Estefa MUÑOZ-GROZA2
VL
Vlad Dumitru BĂLEANU3
VE
Veronica GHEORMAN4
VI
Victor GHEORMAN5
IO
Ion SCURTU6
CO
Corina Lavinia GRUIA7
CA
Camelia Maria FOARFĂ8
DA
Daniel-Cristian PÎRVU9
1 IIIrd General Surgery Clinic, Emergency County Clinical Hospital of Craiova, 1 Tabaci Street, 200642 Craiova, Romania
2 Oncology Departmen t, Filantropia Clinical Hospital, 1 Filantropia Street, 20 0134 Craiova, Romania
3 General Surgery Department, "Sf. Pantelimon" Emergency Clinical Hospital, 340 Sos. Pantelimon, 021659 Bucharest, Romania
4 Cardiology Department , Emergency County Clinical Ho spital of Craiova, 1 Tabaci St reet, 200642 Craiova, Romania
5 Psychiatry Department , University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349
6 Emergency University Hospital Bucharest, Surgery Department, Bucharest, Rom ania, 169 Independe ntei Street, 050098
7 Department of Pathology, Emergency County Clinical Hospital of Craiova, 1 Tabaci Street, 200642 Craiova
8 Department of Pathology, Emergency County Clinical Hospital of Craiova, 1 Tabaci Street, 200642 Cr aiova
9 Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania
Corresponding author: [email protected]
DOI https://doi.org/10.38173/RST.2021.21.1.4:39-52
Received 17 December 2020
Revised -
Accepted 16 February 2021
Available Online 15 March 2021
Abstract
GASTRIC CANCER (CRC) REPRESENTS ONE OF THE MOST COMMONLY DIAGNOSED CANCERS WORLDWIDE. THE TR EATMENT STRATEGY FOR GASTRIC TUMORS HAS CHANGED DURING THE LAST DECADES WITH THE USE OF MOLECULAR PROGNOSTIC FACTORS AND ADEQUATE COMBINATION THERAPIES. CURATIVE THERAPY INVOLVES SURGICAL RESECTION, MOST COMMONLY REPRESENTED BY A TOTAL OR SUBTOTAL GASTRECT OMY WITH AN ACCOMPANYING LYMPHADENECTOMY. MANY STUDIES HAVE INVESTIGATED THE CORRELATION BETWEEN HISTOPATHOLOGICAL CHARACTERISTICS IN GAST RIC CANCER AND PATIENT DATA, DISEASE- SPECIFIC CRITERIA, AND OVERALL OUTCOME. IDENTIFYING PREDICTIVE AND PROGNOSTIC MARKERS IS AN IMPORTANT STEP TO IMPROV E CURRENT TREATMENT APPROACHES AND TO EXTEND SURVIVAL. THEREFORE, WE RET ROSPECTIVELY ANALYZED THE CLINI COPATHOLOGICAL CHARACTERISTICS AND PROGNOSTIC FACTORS AFFECTING THE SURVIVAL RATE OF PATIENTS WITH GASTRIC CANCER.
Keywords
CLINICOPATHOLOGICAL FACTORS GASTRIC CANCER PROGNOSIS SURVIVAL.
Full Text
The body of this article is intentionally hidden on the public page. Please use the PDF reader or the PDF download for the complete text.
References
[1]
Parkin DM, Pisani P, Fer lay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 1993;54:594–606.
[2]
Stewart BW, Kleihues P. World Cancer Report. Lyon: IARC Press; 2003
[3]
Ferlay J, Bray F, Pisani P, Parkin DM . GLOBOCAN 2002: Cancer incidence, mortal ity and prevalence worldwide. Lyon: IARC Press, Cited 2005-04-15; Available from: http: //www-dep.iarc.fr/
[4]
Stomach Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012 . Available from: http://globocan.iarc.fr/old/FactSheets/cancers/stomach-new.asp
[5]
Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Management and Research. 2018;10:239-248. doi:10.2147/CMAR.S149619.
[6]
Brown et Devesa 2002, Brown LM, Devesa SS , Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002 Apr; 11(2):235-56
[7]
Parkin DM, Whelan SL, Ferlay J. Cancer Incidence in Five Continents . Vol V II. Lyon, France: International Agency for Research on Cancer; 1997. pp. 822–82.
[8]
Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23–47.
[9]
Ries LA, Kosary CL, Hankey BF . SEER Cancer Statistics Review 1973 -1995. Bethesda: U.S. Dept. of Health and Human Servi ces, Public Health Service, National Institutes of Health, National C ancer Institute; 1998.
[10]
Verdecchia A, Corazziari I, Gatta G, Lisi D, Faivre J, Forman D . Explaining gastric cancer survival differences among European countries. Int J Cancer. 2004;109:737–741.
[11]
IARC Unit of Descriptive Epidemiology: WHO cancer mortality dat abank. Cancer Mondial, 2001. Available from: http://www-dep.iarc.fr/ataava/globocan/who.html.
[12]
Fielding JWL, Powell J, Allum WH. Cancer of the Stomach. London: The Macmillan Press; 1989.
[13]
Peter Thatcher Stomach Cancer Prognosis By Stage - Life Expectancy, Available from: https://www.mystomachcancersymptoms.com/stomach-cancer-prognosis.html
[14]
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014;64:9–29.
[15]
Van Cutsem E, Sagaer t X, Topal B, Haustermans K, Prenen H . Gastric cancer. Lancet 2016; 388: 2654–64.
[16]
Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F . Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention . Cancer Epidemiol Biomarker s Prev 2014; 23: 700–13.
[17]
Nagel G, Linseisen J, Boshuizen HC, Pera G, Del Giudic e G, Westert GP, Bueno -de-Mesquita HB, Allen NE, Key TJ, Numans ME, Peeters PH, Sieri S, Siman H, Berglund G, Hallmans G, Stenling R, Martinez C, Arriola L, Barricarte A, Chirl aque MD, Quiros JR, Vineis P, Masala G, Palli D, Panico S, Tumino R, Bingham S, Boeing H, Bergmann MM, Overvad K, Boutron -Ruault MC, Clavel-Chapelon F, Olsen A, Tjonneland A, Trichopoulou A, Bamia C, Soukara S, Sabourin JC, Carneiro F, Slimani N, Jenab M, Norat T, Riboli E, Gonzále z CA. Socioeconomic position and the risk o f gastric a nd oesophageal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC -EURGAST). Int J Epidemiol. 2007 Feb;36(1):66 -76. doi: 10.1093/ije/dyl275. Epub 2007 Jan 16. PMID: 17227779.
[18]
Dobru D, Pascu O, Tantau M, Gheorghe C, G oldis A, Balan G, Coman F, Fraticiu A, Dumitru E, Mutescu E, Saftoiu A, Bacarea V. An epidemiological study of gastric cancer in the adult population referred to gastroenterology medical services in Romania -- a multicentric study. Rom J Gastroenterol. 2004 Dec;13(4):275-9. PMID: 15624023.
[19]
Frei, E . Clinical cancer research: an embattled species. Cancer 1982; 50: 1979–1992.
[20]
Lee, HS, Kim, WH, Kwak, Y . Molecular testing for gastrointestinal cancer. J Pathol Transl M ed 2017; 51: 103–121.
[21]
Li, B, Liu, HY, Guo, S H. Detection of microsatellite instability in gastric cancer and dysplasia tissues. Int J Clin Exp Med 2015; 8: 21442–21447.
[22]
Kitamura K, Beppu R, Anai H, Ikejiri K, Yakabe S, Sugimachi K , et al. Clinicopathologic study of patients with Borrmann type IV gastric carcinoma. J Surg Oncol. 1995;58:112–117.
[23]
Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK . Clinicopathologic characteristics and prognostic factors in 10,783 patients with gastric cancer. Gastric Cancer. 1998;1:125–133.
[24]
Abe N., Watanabe T., Suzuki K., Machid a M., Toda H., Nakaya Y., Masaki T., Mori T., Sugiyama M., Atomi Y., Risk factors predictive of lymph node metastasis in depressed early gastric cancer, Am J Surg, 2002, 183(2):168–172.
[25]
Gunderson LL. Gastric cancer -patterns of relapse after surgical resect ion. Semin Radiat Oncol 2002;12:150–61.
[26]
Karpeh MS, Leon L, Klimstra D, Brennan MF . Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patie nts. Ann Surg. 2000;232(3):362 -371. doi:10.1097/00000658-200009000-00008.
[27]
Yasuda K, Adachi Y, Shiraishi N, Maeo S, Kitano S . Papillary adenocarcinoma of the stomach. Gastric Cancer. 2000;3:33–38.
[28]
Kawamura H, Kondo Y, Osawa S, Nisida Y, Okada K, Isizu H, Uebayasi T, Takahasi M, Hata T . A clinicopathologic study of mucinous adenocarcinoma of the stomach. Gastric Cancer. 2001;4:83–86.
[29]
Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP . Gastric cancer: epidemiology, prevention, classi fication, and treatment. Cancer Manag Res. 2018;10:239 -248. Published 2018 Feb 7. doi:10.2147/CMAR.S149619.